Back to top

Image: Bigstock

Should Value Investors Pick Amneal Pharma (AMRX) Stock Now?

Read MoreHide Full Article

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Amneal Pharmaceuticals (AMRX - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Amneal Pharmaceuticals has a trailing twelve months PE ratio of 10.47, as you can see in the chart below:


 
This level actually compares favorably with the market at large, as the PE for the S&P 500 stands at about 20.53. If we focus on the long-term PE trend, Amneal Pharmaceuticals’ current PE level puts it below its midpoint of 23.28 over the past five years, with the number having risen rapidly over the past few months. However, the current level stands significantly below the highs for the stock, suggesting that it can be a solid entry point.


 
Moreover, the stock’s PE also compares favorably with the Zacks Medical Market sector’s trailing twelve months PE ratio, which stands at 23.26. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.


 
We should also point out that Amneal Pharmaceuticals has a forward PE ratio (price relative to this year’s earnings) of 10.06, so it is fair to say that a slightly more value-oriented path may be ahead for Amneal Pharmaceuticals’ stock in the near term too.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Amneal Pharmaceuticals has a P/S ratio of about 0.39. This is much lower than the S&P 500 average, which comes in at 3.55 right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.


 
Broad Value Outlook

In aggregate, Amneal Pharmaceuticals currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Amneal Pharmaceuticals a solid choice for value investors.

For example, the PEG ratio for Amneal Pharmaceuticals is just 0.69, a level that is lower than the industry average of 1.69. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 3.52, which is better than the industry average of 10.63. Clearly, AMRX is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though Amneal Pharmaceuticals might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and Momentum Score of F. This gives AMRX a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more
about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been encouraging. The current year has seen two upward revisions in the past sixty days compared to one downward revision, while the full year 2021 estimate has also seen two upward revisions compared to one downward revision in the same time period.

You can see the consensus estimate trend and recent price action for the stock in the chart below:

AMNEAL PHARMACEUTICALS, INC. Price and Consensus

Notably, the stock with a solid earnings surprise history and favorable estimate trends has a Zacks Rank #2 (Buy), which is why we are looking for outperformance from the company in the near term.

Bottom Line

Amneal Pharmaceuticals is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Furthermore, the Zacks Rank #2 company (with a favorable industry rank of 40%) indicates that the broader factors are favorable for the company.

So, value investors might want to delve deeper in this stock as it appears to be a compelling pick.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>


More In-Depth Research from Zacks


Normally $25 each - click below to receive one report FREE:


AMNEAL PHARMACEUTICALS, INC. (AMRX) - free report >>

Published in